Related references
Note: Only part of the references are listed.Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
John F. R. Robertson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
miR-22 Inhibits Estrogen Signaling by Directly Targeting the Estrogen Receptor α mRNA
Deo Prakash Pandey et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Repression of ESR1 through Actions of Estrogen Receptor Alpha and Sin3A at the Proximal Promoter
Stephanie J. Ellison-Zelski et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
RelB NF-κB Represses Estrogen Receptor α Expression via Induction of the Zinc Finger Protein Blimp1
Xiaobo Wang et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Revealing targeted therapy for human cancer by gene module maps
David J. Wong et al.
CANCER RESEARCH (2008)
miR-206 expression is down-regulated in estrogen receptor α-positive human breast cancer
Naoto Kondo et al.
CANCER RESEARCH (2008)
Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT
Stephen Chia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-α expression in breast cancer cells
Youqi Han et al.
MOLECULAR CANCER RESEARCH (2008)
Diminished feedback regulation of proteasome expression and resistance to proteasome inhibitors in breast cancer cells
Haiming Xu et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Temporal variation in estrogen receptor-alpha protein turnover in the presence of estrogen
Christopher C. Valley et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2008)
A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience
Ryan H. Engel et al.
CANCER INVESTIGATION (2007)
The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-α
Archana Dhasarathy et al.
MOLECULAR ENDOCRINOLOGY (2007)
Estrogen insensitivity in a model of estrogen receptor-positive breast cancer lymph node metastasis
Joshua Chuck Harrell et al.
CANCER RESEARCH (2007)
Estrogen receptor DNA binding is not required for estrogen-induced breast cell growth
David G. DeNardo et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2007)
Estrogen receptor-α expression in the mammary epithelium is required for ductal and alveolar morphogenesis in mice
Yuxin Feng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:: BIG 1-98
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Alterations of gene expression in the development of early hyperplastic precursors of breast cancer
Sangjun Lee et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Proteasome-regulated ERBB2 and estrogen receptor pathways in breast cancer
Corina Marx et al.
MOLECULAR PHARMACOLOGY (2007)
The micro-ribonucleic acid (miRNA) miR-206 targets the human estrogen receptor-α (ERα) and represses ERα messenger RNA and protein expression in breast cancer cell lines
Brian D. Adams et al.
MOLECULAR ENDOCRINOLOGY (2007)
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer:: Update of study BIG 1-98
Alan S. Coates et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Bortezomib (PS-341, Velcade) increases the efficacy of trastuzumab (Herceptin) in HER-2-positive breast cancer cells in a synergistic manner
Fatima Cardoso et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Bortezomib (VELCADE®) in metastatic breast cancer:: pharmacodynamics, biological effects, and prediction of clinical benefits
CH Yang et al.
ANNALS OF ONCOLOGY (2006)
Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis
M Bazzaro et al.
CANCER RESEARCH (2006)
Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate
AF Kisselev et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells
J Codony-Servat et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Statistical analysis of real-time PCR data
JS Yuan et al.
BMC BIOINFORMATICS (2006)
Altered target gene regulation controlled by estrogen receptor-α concentration
AM Fowler et al.
MOLECULAR ENDOCRINOLOGY (2006)
Lives and times of nuclear receptors
Elaine T. Alarid
MOLECULAR ENDOCRINOLOGY (2006)
Hormones, receptors, and growth in hyperplastic enlarged lobular units: early potential precursors of breast cancer
S Lee et al.
BREAST CANCER RESEARCH (2006)
Estrogen receptor-α mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen
AJM O'Donnell et al.
ENDOCRINE-RELATED CANCER (2005)
Differential regulation of estrogen-inducible proteolysis and transcription by the estrogen receptor α N terminus
CC Valley et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
Increased proteasome activity, ubiquitin-conjugating enzymes, and eEF1A translation factor detected in breast cancer tissue
L Chen et al.
CANCER RESEARCH (2005)
Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors
MH Shah et al.
CLINICAL CANCER RESEARCH (2004)
Inhibiting proteasomal proteolysis sustains estrogen receptor-α activation
MY Fan et al.
MOLECULAR ENDOCRINOLOGY (2004)
Estrogen receptor-α directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter
R Métivier et al.
CELL (2003)
Increased muscle proteasome activity correlates with disease severity in gastric cancer patients
M Bossola et al.
ANNALS OF SURGERY (2003)
Cyclic, proteasome-mediated turnover of unliganded and liganded ERα on responsive promoters is an integral feature of estrogen signaling
G Reid et al.
MOLECULAR CELL (2003)
Secretory leucoprotease inhibitor prevents lipopolysaccharide-induced IκBα degradation without affecting phosphorylation or ubiquitination
CC Taggart et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Estrogen up-regulation of p53 gene expression in MCF-7 breast cancer cells is mediated, by calmodulin kinase IV-dependent activation of a nuclear factor κB/CCAAT-binding transcription factor-1 complex
CH Qin et al.
MOLECULAR ENDOCRINOLOGY (2002)
Breast cancer risk in usual ductal hyperplasia is defined by estrogen receptor-α and Ki-67 expression
AM Shaaban et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method
KJ Livak et al.
METHODS (2001)
Minireview:: genomic organization of the human ERα gene promoter region
M Kos et al.
MOLECULAR ENDOCRINOLOGY (2001)
ERα gene expression in human primary osteoblasts:: Evidence for the expression of two receptor proteins
S Denger et al.
MOLECULAR ENDOCRINOLOGY (2001)
The human estrogen receptor-α is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators
AL Wijayaratne et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation
DM Lonard et al.
MOLECULAR CELL (2000)
Share Paper
